Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Earnings

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

By The Northwire Desk — AI Analysis Feb 13, 2026 · 08:09 MDNA · 0.76 MEDICENNA THERAPEUTICS CORP. J
MDNA · Price

Executive Summary

  • Updated ABILITY‑1 expansion cohort data show MDNA11 achieving ORR 36% (monotherapy) and 43% (with pembrolizumab) in 14 patients, with high disease control rates.
  • Bizaxofusp (MDNA55) Phase 2b trial in recurrent GBM demonstrated a doubling of median overall survival to 13.6 months versus 7 months standard‑of‑care.
  • Cash and cash equivalents of $10.6 million provide runway into Q3 2026; net loss narrowed to $4.4 million for the quarter ended Dec 31 2025.

Key Details

  • Clinical Data – MDNA11 (ABILITY‑1):
  • Monotherapy ORR 36% and DCR 86% (N=14).
  • Combination with pembrolizumab ORR 43% and DCR 72% (N=14).

  • Expansion cohorts now enrolling MSI‑H, TMB‑H, cutaneous melanoma, endometrial (combo), NSCLC (combo), colorectal (mono & combo).

  • Pipeline Additions:

  • New ABILITY‑1 expansion cohort for NSCLC patients with secondary checkpoint resistance.

  • NEO‑CYT trial (Fondazione Melanoma Onlus) – front‑line neoadjuvant MDNA11 + nivolumab ± ipilimumab in Stage III melanoma; enrollment H1 2026, interim data H2 2026.

  • Pre‑clinical Asset – MDNA113:

  • First‑in‑class tumor‑anchored anti‑PD‑1–IL‑2 bifunctional superkine.

  • Favorable safety in non‑human primates at 30 mg/kg; IND filing planned for H2 2026.

  • Bizaxofusp (MDNA55) – Glioblastoma:

  • Phase 2b trial (N=44) in non‑resectable recurrent GBM showed median OS of 13.6 months vs. 7 months standard care.

  • Presentation of updated data at the 7th Annual Glioblastoma Development Summit, Boston, Feb 17‑19 2026.

  • Financial Results (Quarter ended Dec 31 2025):

  • Cash & cash equivalents: $10.6 million → runway to Q3 2026.
  • Operating costs: $5.6 million (up from $5.1 M YoY).
  • R&D expenses: $4.1 million (↑$0.5 M YoY) – driven by MDNA11 expansion and NEO‑CYT initiation.

  • Net loss: $4.4 million ($0.05/share), improvement of $0.8 million vs. prior year.

  • Board Changes:

  • Appointments of Richard Sutin and Angelos Georgakis to the Board of Directors, following retirement of Karen Dawes.

Notable Quotes

“We delivered strong clinical results in 2025 with our ABILITY‑1 trial and 2026 is shaping up to be a milestone‑rich year across our pipeline,” – Dr. Fahar Merchant, President & CEO, Medicenna Therapeutics.

All forward‑looking statements are subject to risks and uncertainties detailed in the company’s filings.

Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 19, 2026 · 07:00

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

Financings